Skip to main content

Advertisement

Table 1 Renal drug guidelines, entry criteria, mean estimated glomerular filtration rate, and composite outcome definitions in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients–Removing Excess Glucose (EMPA–REG OUTCOME), and Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trials

From: Class effects of SGLT2 inhibitors on cardiorenal outcomes

Trial FDA indicated guidelines Study renal entry criteria Results
Minimum recommended eGFR eGFR minimum eGFR equation Additional renal criteria Mean eGFR Composite renal outcome
DECLARE-TIMI 58 45 N/A CKD-EPI CrCl 60 mL/min (Cockroft-Gault equation) 85.2 ≥ 40% reduction in eGFR to < 60, ESRD (dialysis ≥ 90 days, transplant or sustained eGFR < 15), or renal/CV death
CANVAS 45 30 MDRD N/A 76.5 ≥ 40% reduction in eGFR, RRT (transplant, chronic dialysis, or sustained eGFR < 15), or renal death
EMPA–REG OUTCOME 45 30 MDRD N/A 74 Doubling of serum Cr with eGFR ≤ 45, RRT, or renal death
CREDENCE 45 30 CKD-EPI UACR 300–5000 56.2 Doubling of serum Cr, ESRD (eGFR < 15, dialysis, or renal transplant), renal/CV death
  1. All eGFRs are in mL/min/1.73 m2
  2. eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease, CKD-EPI chronic kidney disease epidemiology collaboration, RRT renal-replacement therapy, ESRD end-stage renal disease, CV cardiovascular, CrCl creatinine clearance, Cr creatinine, UACR urinary albumin-creatinine ratio in mg/g